Adherence to the multi-target stool DNA test in the US Hispanic population from 2016-2024.

M Mark Camardo (Exact Sciences Corporation, Madison, WI) M Mallik Greene (Exact Sciences Corporation, Madison, WI) W William K Johnson (Exact Sciences Corporation, Madison, WI) A A Burak Ozbay (Exact Sciences Corporation, Madison, WI) J Juliana Vanessa Rincón López (Unisanitas, Bogota, Colombia) P Paul J. Limburg (Exact Sciences Corp., Madison, WI) M Martha Duarte (Sanitas USA/Keralty Hospital, Miami, FL)

Abstract

100 Background: With colorectal cancer (CRC) as the second most common cause of cancer-related mortality in the US, adherence to CRC screening is a vital component to alleviating the cancer burden. Statistics show that only 52% of Hispanic or Latino individuals ≥45 years were up-to-date with CRC screening in 2021. A guideline-recommended, at-home CRC screening option, such as the multi-target stool DNA test (mt-sDNA), could be an efficient modality for screening average-risk individuals. Using a large national claims database, we examined CRC screening adherence with mt-sDNA in the US Hispanic population. Methods: Data was sourced from a database of over 165 million individuals linked with Exact Sciences Laboratories data. Hispanic persons who received mt-sDNA orders and resided in the US were retrospectively identified from 2016 to 2024. The analyses included persons who were ≥45 years of age, new to mt-sDNA and average risk for CRC during the 12-month pre-index period. Primary outcome of interest was adherence, which was defined as the mt-sDNA kit return rate within 365-days from shipment. All patients received a mailed letter along with digital outreach through the accompanying patient navigation program, according to their communication preference. The modes of digital outreach included: SMS, email, or both. Baseline demographics collected included age, sex, ordering provider, residential geography, payor, and outreach preference. Adjusted analyses were used to examine effects of covariates on adherence. Results: A total of 447,968 mt-sDNA orders were shipped during the study period and the overall adherence rate was 62.5%. Average time to test return was 28.5 days. Women comprised the majority of the cohort (59.9%), resided mostly in the Southern US (46.9%), aged 50-64 (60.9%), resided in a metropolitan area (91.2%), and received their mt-sDNA order from their primary care provider (62.7%). Across evaluated age groups, adherence was above 60% for all: ages 45-49 [60.5%]; 50-64 [62.6%], 65-75 [62.6%]), and ≥ 76 years [66.8]. By payor, Medicare-insured patients demonstrated the highest adherence (65.5%). Digital SMS was the preferred contact method (51.2%), and those opting for SMS + Email had the highest adherence rate (64.2%). Of provider specialties, individuals having their tests ordered by GIs produced the shortest time to adherence (23.2 days). Regression analyses revealed that older age (≥ 76 years), living in a rural area, and receiving fully or partially digital outreach were associated with increased mt-sDNA adherence. Conclusions: This large, national analysis reveals high mt-sDNA adherence amongst Hispanic individuals in the US, despite reports of low national CRC screening rates in this population. These data support the important role of mt-sDNA in facilitating screening engagement, while emphasizing the importance of preference-based navigation in facilitating screening test completion.

Article Details

Volume / Issue Vol. 43, Issue 4_suppl
Published February 01, 2025
Pages 100-100
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (7)

M

Mark Camardo

Exact Sciences Corporation, Madison, WI

M

Mallik Greene

Exact Sciences Corporation, Madison, WI

W

William K Johnson

Exact Sciences Corporation, Madison, WI

A

A Burak Ozbay

Exact Sciences Corporation, Madison, WI

J

Juliana Vanessa Rincón López

Unisanitas, Bogota, Colombia

P

Paul J. Limburg

Exact Sciences Corp., Madison, WI

M

Martha Duarte

Sanitas USA/Keralty Hospital, Miami, FL